Caris Life Sciences published pioneering data validating its platform for minimal residual disease detection and early cancer identification with commercial launches anticipated soon. Concurrently, the University of Chicago spinout OrisDx is preparing to launch a saliva-based oral cancer test using next-generation sequencing, aimed at early detection and reducing unnecessary biopsies. These developments signal progress in non-invasive diagnostics and enhanced cancer monitoring solutions.